Merit Medical Systems (NASDAQ:MMSI – Get Free Report) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Merit Medical Systems’ Q4 2026 earnings at $0.98 EPS, FY2026 earnings at $3.73 EPS, Q1 2027 earnings at $0.88 EPS, Q2 2027 earnings at $1.02 EPS, Q3 2027 earnings at $1.01 EPS, Q4 2027 earnings at $1.10 EPS, FY2027 earnings at $4.01 EPS, Q1 2028 earnings at $0.95 EPS, Q2 2028 earnings at $1.11 EPS and FY2028 earnings at $4.32 EPS.
A number of other research firms also recently weighed in on MMSI. Needham & Company LLC boosted their target price on Merit Medical Systems from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. increased their price target on shares of Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Bank of America lifted their price target on shares of Merit Medical Systems from $92.00 to $97.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Barrington Research set a $114.00 price objective on shares of Merit Medical Systems in a research note on Friday, July 31st. Finally, Canaccord Genuity Group increased their target price on shares of Merit Medical Systems from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $100.00.
Check Out Our Latest Analysis on Merit Medical Systems
Merit Medical Systems Stock Performance
Merit Medical Systems (NASDAQ:MMSI – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a return on equity of 13.75% and a net margin of 9.22%.The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, equities research analysts predict that Merit Medical Systems will post 3.84 EPS for the current fiscal year.
Institutional Investors Weigh In On Merit Medical Systems
Several institutional investors and hedge funds have recently bought and sold shares of the business. Los Angeles Capital Management LLC bought a new stake in shares of Merit Medical Systems in the 4th quarter worth approximately $25,000. Kilter Group LLC bought a new position in shares of Merit Medical Systems during the second quarter valued at approximately $25,000. Torren Management LLC purchased a new stake in Merit Medical Systems in the fourth quarter worth $38,000. Covestor Ltd boosted its holdings in Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 336 shares in the last quarter. Finally, Danske Bank A S bought a new stake in Merit Medical Systems in the third quarter valued at $42,000. Hedge funds and other institutional investors own 99.66% of the company’s stock.
Trending Headlines about Merit Medical Systems
Here are the key news stories impacting Merit Medical Systems this week:
- Positive Sentiment: Zacks Research raised several earnings forecasts. The firm increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. It also lifted estimates for Q2 2027, Q3 2027, Q1 2028, and Q2 2028. The revisions suggest improved confidence in Merit Medical’s longer-term earnings growth.
- Positive Sentiment: Longer-term earnings expectations are moving higher. The revised FY2027 and FY2028 forecasts exceed the current-year consensus estimate of roughly $3.81–$3.84 per share, reinforcing the outlook for continued earnings expansion.
- Neutral Sentiment: Short-interest data appears unusable. The report lists short interest at zero shares and describes the change as “NaN,” with a zero days-to-cover ratio. This does not provide a meaningful signal about short-selling pressure or potential short covering.
- Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q4 2026 EPS forecast slightly to $0.98 from $0.99. While the change is minor, it offsets some of the broader positive revisions and indicates limited near-term earnings impact.
- Negative Sentiment: Valuation leaves less room for disappointment. Merit Medical’s shares recently traded near their 52-week high, with a P/E ratio above 37 and a PEG ratio above 2. Stronger earnings expectations are supportive, but the premium valuation could weigh on the stock if results or guidance fall short.
Merit Medical Systems Company Profile
Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.
Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.
Featured Stories
- Five stocks we like better than Merit Medical Systems
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
